Sinobioway Medicine equity case second instance retrial: revocation of embezzlement charge, reduced prison term and fineWallstreetcn·Jan 2 at 05:15 AM002581+3.64%
The flu vaccine has a "freezing point price" of 5.5 yuan36Kr·Sep 3, 2025 at 10:21 PM002007-0.30%002581+3.64%
Sinobioway Medicine: Net loss of 67.3027 million yuan in the first half of 2025Zhitong·Aug 19, 2025 at 05:44 AM002581+3.64%
Sinovac's combined hepatitis A and B vaccine, Beirlaifu, is re-registered for market launchZhitong·Jul 31, 2025 at 04:36 AM002581+3.64%
ST Sinobioway Medicine: Tianjin Sinobioway is subject to other risk warningsZhitong·Jul 10, 2025 at 06:48 AM002581+3.64%
Sinobioway Medicine has been subjected to other risk warnings, and its stock abbreviation has been changed to "ST Sinobioway"Zhitong·Jul 4, 2025 at 08:55 AM002581+3.64%
The innovative drug sector opened high again, Thalys has achieved a 4-day consecutive limit upZhitong·Jul 3, 2025 at 08:28 PM301263+6.00%300436+3.42%
Sinobioway Medicine: The company is at risk of triggering other risk warningsZhitong·Jul 3, 2025 at 08:06 AM002581+3.64%
Innovative drug concept stocks are repeatedly active, Thalys has three consecutive limit-upsZhitong·Jul 2, 2025 at 08:42 PM300485+3.29%603716+3.38%
Sinobioway Medicine's subsidiary plans to acquire a 51% stake in Traditional Chinese Medicine enterprise Gukan PharmaceuticalZhitong·Jun 24, 2025 at 06:05 AM002581+3.64%
Sinobioway Medicine's subsidiary Tianjin Sinobioway was suspended from production and sales by the Tianjin Municipal Drug Administration on April 22, 2025. Tianjin Sinobioway mainly engages in the production and sales of human interferon drugs, achieving an operating income of 216.5683 million yuan and a net profit of -14.0037 million yuan in 2024, accounting for 60.09% of the company's operating income and 9.8% of the consolidated net profit, respectively. This suspension has a significant impact on the company's operationsWallstreetcn·May 23, 2025 at 06:46 AM002581+3.64%
Sinobioway Medicine received a dividend payment of 135 million yuan from Beijing KexingZhitong·May 16, 2025 at 07:36 AM002581+3.64%
CRO concept stocks opened lower, SC Pharmaceuticals and Sinobioway Medicine hit the daily limit downZhitong·Apr 27, 2025 at 08:30 PM002581+3.64%002693+1.78%
Sinobioway Medicine: The Tianjin Municipal Medical Products Administration has decided to implement risk control measures to suspend production and sales of Tianjin Sinobioway Biopharmaceutical Co., Ltd. The company's main business has been severely affected due to the suspension of production at Tianjin SinobiowayWallstreetcn·Apr 24, 2025 at 06:58 AM002581+3.64%
Sinobioway Medicine plans to sign a sales contract with Jiangsu Suhao, with a total contract price of 53.978 million yuanZhitong·Mar 12, 2025 at 06:49 AM002581+3.64%
